Review



anti murine c5ar2  (Hycult Biotech)


Bioz Verified Symbol Hycult Biotech is a verified supplier
Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Hycult Biotech anti murine c5ar2
    Decay-accelerating factor (DAF) is required for the tolerogenic properties of CD103+ dendritic cells (DCs) and regulatory T cells. A–C: CD11c+ DCs harvested from the eyes (A), draining submandibular lymph nodes (smLNs; B), and mesenteric lymph nodes (mLNs; C) of wild-type (WT), Daf1–/–, and Daf1–/–C3ar1–/–C5ar1–/– mice were assayed for CD40, B7.1, B7.2, major histocompatibility complex (MHC) II, PD-L1, and ICOS-L by flow cytometry (Daf1–/– versus WT and Daf1–/–C3ar1–/–C5ar1–/– versus WT). D–F: CD11b+F4/80+ macrophages harvested from the eyes (D), draining smLNs (E), and mLNs (F) of WT, Daf1–/–, and Daf1–/–C3ar1–/–C5ar1–/– mice were assayed for the same markers. Cells were also assayed for C5ar1 and <t>C5L2.</t> The fact that differences in ICOS-L levels between Daf1−/− and WT cells reach statistical significance reflects mouse numbers as other studies in the laboratory (M.G.S., J.L., F.A., and M.E.M., unpublished data) reproducibly have documented statistical significance. G and H: Human plasmacytoid DCs (pDCs; G) and CD4 T cells (H) were treated with siRNA targeting DAF or C3ar1 and C5ar1 for 72 hours, after which expression of CD40, B7.1, B7.2, CCR7, CCR9, PD-L1, and ICOS-L on pDCs (G) and expression of CD28, CD40 ligand, CCR7, CCR9, PD-1, and ICOS on CD4+ T cells (H) was assessed by flow cytometry. n = 10 per group (A–F); n = 3 (G and H). ∗∗P < 0.01. MFI, mean fluorescent intensity.
    Anti Murine C5ar2, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti murine c5ar2/product/Hycult Biotech
    Average 90 stars, based on 1 article reviews
    anti murine c5ar2 - by Bioz Stars, 2025-02
    90/100 stars

    Images

    1) Product Images from "CD55 Is Essential for CD103 + Dendritic Cell Tolerogenic Responses that Protect against Autoimmunity"

    Article Title: CD55 Is Essential for CD103 + Dendritic Cell Tolerogenic Responses that Protect against Autoimmunity

    Journal: The American Journal of Pathology

    doi: 10.1016/j.ajpath.2019.04.008

    Decay-accelerating factor (DAF) is required for the tolerogenic properties of CD103+ dendritic cells (DCs) and regulatory T cells. A–C: CD11c+ DCs harvested from the eyes (A), draining submandibular lymph nodes (smLNs; B), and mesenteric lymph nodes (mLNs; C) of wild-type (WT), Daf1–/–, and Daf1–/–C3ar1–/–C5ar1–/– mice were assayed for CD40, B7.1, B7.2, major histocompatibility complex (MHC) II, PD-L1, and ICOS-L by flow cytometry (Daf1–/– versus WT and Daf1–/–C3ar1–/–C5ar1–/– versus WT). D–F: CD11b+F4/80+ macrophages harvested from the eyes (D), draining smLNs (E), and mLNs (F) of WT, Daf1–/–, and Daf1–/–C3ar1–/–C5ar1–/– mice were assayed for the same markers. Cells were also assayed for C5ar1 and C5L2. The fact that differences in ICOS-L levels between Daf1−/− and WT cells reach statistical significance reflects mouse numbers as other studies in the laboratory (M.G.S., J.L., F.A., and M.E.M., unpublished data) reproducibly have documented statistical significance. G and H: Human plasmacytoid DCs (pDCs; G) and CD4 T cells (H) were treated with siRNA targeting DAF or C3ar1 and C5ar1 for 72 hours, after which expression of CD40, B7.1, B7.2, CCR7, CCR9, PD-L1, and ICOS-L on pDCs (G) and expression of CD28, CD40 ligand, CCR7, CCR9, PD-1, and ICOS on CD4+ T cells (H) was assessed by flow cytometry. n = 10 per group (A–F); n = 3 (G and H). ∗∗P < 0.01. MFI, mean fluorescent intensity.
    Figure Legend Snippet: Decay-accelerating factor (DAF) is required for the tolerogenic properties of CD103+ dendritic cells (DCs) and regulatory T cells. A–C: CD11c+ DCs harvested from the eyes (A), draining submandibular lymph nodes (smLNs; B), and mesenteric lymph nodes (mLNs; C) of wild-type (WT), Daf1–/–, and Daf1–/–C3ar1–/–C5ar1–/– mice were assayed for CD40, B7.1, B7.2, major histocompatibility complex (MHC) II, PD-L1, and ICOS-L by flow cytometry (Daf1–/– versus WT and Daf1–/–C3ar1–/–C5ar1–/– versus WT). D–F: CD11b+F4/80+ macrophages harvested from the eyes (D), draining smLNs (E), and mLNs (F) of WT, Daf1–/–, and Daf1–/–C3ar1–/–C5ar1–/– mice were assayed for the same markers. Cells were also assayed for C5ar1 and C5L2. The fact that differences in ICOS-L levels between Daf1−/− and WT cells reach statistical significance reflects mouse numbers as other studies in the laboratory (M.G.S., J.L., F.A., and M.E.M., unpublished data) reproducibly have documented statistical significance. G and H: Human plasmacytoid DCs (pDCs; G) and CD4 T cells (H) were treated with siRNA targeting DAF or C3ar1 and C5ar1 for 72 hours, after which expression of CD40, B7.1, B7.2, CCR7, CCR9, PD-L1, and ICOS-L on pDCs (G) and expression of CD28, CD40 ligand, CCR7, CCR9, PD-1, and ICOS on CD4+ T cells (H) was assessed by flow cytometry. n = 10 per group (A–F); n = 3 (G and H). ∗∗P < 0.01. MFI, mean fluorescent intensity.

    Techniques Used: Flow Cytometry, Expressing



    Similar Products

    90
    Hycult Biotech anti murine c5ar2
    Decay-accelerating factor (DAF) is required for the tolerogenic properties of CD103+ dendritic cells (DCs) and regulatory T cells. A–C: CD11c+ DCs harvested from the eyes (A), draining submandibular lymph nodes (smLNs; B), and mesenteric lymph nodes (mLNs; C) of wild-type (WT), Daf1–/–, and Daf1–/–C3ar1–/–C5ar1–/– mice were assayed for CD40, B7.1, B7.2, major histocompatibility complex (MHC) II, PD-L1, and ICOS-L by flow cytometry (Daf1–/– versus WT and Daf1–/–C3ar1–/–C5ar1–/– versus WT). D–F: CD11b+F4/80+ macrophages harvested from the eyes (D), draining smLNs (E), and mLNs (F) of WT, Daf1–/–, and Daf1–/–C3ar1–/–C5ar1–/– mice were assayed for the same markers. Cells were also assayed for C5ar1 and <t>C5L2.</t> The fact that differences in ICOS-L levels between Daf1−/− and WT cells reach statistical significance reflects mouse numbers as other studies in the laboratory (M.G.S., J.L., F.A., and M.E.M., unpublished data) reproducibly have documented statistical significance. G and H: Human plasmacytoid DCs (pDCs; G) and CD4 T cells (H) were treated with siRNA targeting DAF or C3ar1 and C5ar1 for 72 hours, after which expression of CD40, B7.1, B7.2, CCR7, CCR9, PD-L1, and ICOS-L on pDCs (G) and expression of CD28, CD40 ligand, CCR7, CCR9, PD-1, and ICOS on CD4+ T cells (H) was assessed by flow cytometry. n = 10 per group (A–F); n = 3 (G and H). ∗∗P < 0.01. MFI, mean fluorescent intensity.
    Anti Murine C5ar2, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti murine c5ar2/product/Hycult Biotech
    Average 90 stars, based on 1 article reviews
    anti murine c5ar2 - by Bioz Stars, 2025-02
    90/100 stars
      Buy from Supplier

    90
    Hycult Biotech rabbit unlabeled polyclonal ab against c5ar2
    Decay-accelerating factor (DAF) is required for the tolerogenic properties of CD103+ dendritic cells (DCs) and regulatory T cells. A–C: CD11c+ DCs harvested from the eyes (A), draining submandibular lymph nodes (smLNs; B), and mesenteric lymph nodes (mLNs; C) of wild-type (WT), Daf1–/–, and Daf1–/–C3ar1–/–C5ar1–/– mice were assayed for CD40, B7.1, B7.2, major histocompatibility complex (MHC) II, PD-L1, and ICOS-L by flow cytometry (Daf1–/– versus WT and Daf1–/–C3ar1–/–C5ar1–/– versus WT). D–F: CD11b+F4/80+ macrophages harvested from the eyes (D), draining smLNs (E), and mLNs (F) of WT, Daf1–/–, and Daf1–/–C3ar1–/–C5ar1–/– mice were assayed for the same markers. Cells were also assayed for C5ar1 and <t>C5L2.</t> The fact that differences in ICOS-L levels between Daf1−/− and WT cells reach statistical significance reflects mouse numbers as other studies in the laboratory (M.G.S., J.L., F.A., and M.E.M., unpublished data) reproducibly have documented statistical significance. G and H: Human plasmacytoid DCs (pDCs; G) and CD4 T cells (H) were treated with siRNA targeting DAF or C3ar1 and C5ar1 for 72 hours, after which expression of CD40, B7.1, B7.2, CCR7, CCR9, PD-L1, and ICOS-L on pDCs (G) and expression of CD28, CD40 ligand, CCR7, CCR9, PD-1, and ICOS on CD4+ T cells (H) was assessed by flow cytometry. n = 10 per group (A–F); n = 3 (G and H). ∗∗P < 0.01. MFI, mean fluorescent intensity.
    Rabbit Unlabeled Polyclonal Ab Against C5ar2, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit unlabeled polyclonal ab against c5ar2/product/Hycult Biotech
    Average 90 stars, based on 1 article reviews
    rabbit unlabeled polyclonal ab against c5ar2 - by Bioz Stars, 2025-02
    90/100 stars
      Buy from Supplier

    90
    Hycult Biotech polyclonal antibody
    Decay-accelerating factor (DAF) is required for the tolerogenic properties of CD103+ dendritic cells (DCs) and regulatory T cells. A–C: CD11c+ DCs harvested from the eyes (A), draining submandibular lymph nodes (smLNs; B), and mesenteric lymph nodes (mLNs; C) of wild-type (WT), Daf1–/–, and Daf1–/–C3ar1–/–C5ar1–/– mice were assayed for CD40, B7.1, B7.2, major histocompatibility complex (MHC) II, PD-L1, and ICOS-L by flow cytometry (Daf1–/– versus WT and Daf1–/–C3ar1–/–C5ar1–/– versus WT). D–F: CD11b+F4/80+ macrophages harvested from the eyes (D), draining smLNs (E), and mLNs (F) of WT, Daf1–/–, and Daf1–/–C3ar1–/–C5ar1–/– mice were assayed for the same markers. Cells were also assayed for C5ar1 and <t>C5L2.</t> The fact that differences in ICOS-L levels between Daf1−/− and WT cells reach statistical significance reflects mouse numbers as other studies in the laboratory (M.G.S., J.L., F.A., and M.E.M., unpublished data) reproducibly have documented statistical significance. G and H: Human plasmacytoid DCs (pDCs; G) and CD4 T cells (H) were treated with siRNA targeting DAF or C3ar1 and C5ar1 for 72 hours, after which expression of CD40, B7.1, B7.2, CCR7, CCR9, PD-L1, and ICOS-L on pDCs (G) and expression of CD28, CD40 ligand, CCR7, CCR9, PD-1, and ICOS on CD4+ T cells (H) was assessed by flow cytometry. n = 10 per group (A–F); n = 3 (G and H). ∗∗P < 0.01. MFI, mean fluorescent intensity.
    Polyclonal Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal antibody/product/Hycult Biotech
    Average 90 stars, based on 1 article reviews
    polyclonal antibody - by Bioz Stars, 2025-02
    90/100 stars
      Buy from Supplier

    90
    Hycult Biotech polyclonal antibody against mouse c5l2
    Decay-accelerating factor (DAF) is required for the tolerogenic properties of CD103+ dendritic cells (DCs) and regulatory T cells. A–C: CD11c+ DCs harvested from the eyes (A), draining submandibular lymph nodes (smLNs; B), and mesenteric lymph nodes (mLNs; C) of wild-type (WT), Daf1–/–, and Daf1–/–C3ar1–/–C5ar1–/– mice were assayed for CD40, B7.1, B7.2, major histocompatibility complex (MHC) II, PD-L1, and ICOS-L by flow cytometry (Daf1–/– versus WT and Daf1–/–C3ar1–/–C5ar1–/– versus WT). D–F: CD11b+F4/80+ macrophages harvested from the eyes (D), draining smLNs (E), and mLNs (F) of WT, Daf1–/–, and Daf1–/–C3ar1–/–C5ar1–/– mice were assayed for the same markers. Cells were also assayed for C5ar1 and <t>C5L2.</t> The fact that differences in ICOS-L levels between Daf1−/− and WT cells reach statistical significance reflects mouse numbers as other studies in the laboratory (M.G.S., J.L., F.A., and M.E.M., unpublished data) reproducibly have documented statistical significance. G and H: Human plasmacytoid DCs (pDCs; G) and CD4 T cells (H) were treated with siRNA targeting DAF or C3ar1 and C5ar1 for 72 hours, after which expression of CD40, B7.1, B7.2, CCR7, CCR9, PD-L1, and ICOS-L on pDCs (G) and expression of CD28, CD40 ligand, CCR7, CCR9, PD-1, and ICOS on CD4+ T cells (H) was assessed by flow cytometry. n = 10 per group (A–F); n = 3 (G and H). ∗∗P < 0.01. MFI, mean fluorescent intensity.
    Polyclonal Antibody Against Mouse C5l2, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal antibody against mouse c5l2/product/Hycult Biotech
    Average 90 stars, based on 1 article reviews
    polyclonal antibody against mouse c5l2 - by Bioz Stars, 2025-02
    90/100 stars
      Buy from Supplier

    Image Search Results


    Decay-accelerating factor (DAF) is required for the tolerogenic properties of CD103+ dendritic cells (DCs) and regulatory T cells. A–C: CD11c+ DCs harvested from the eyes (A), draining submandibular lymph nodes (smLNs; B), and mesenteric lymph nodes (mLNs; C) of wild-type (WT), Daf1–/–, and Daf1–/–C3ar1–/–C5ar1–/– mice were assayed for CD40, B7.1, B7.2, major histocompatibility complex (MHC) II, PD-L1, and ICOS-L by flow cytometry (Daf1–/– versus WT and Daf1–/–C3ar1–/–C5ar1–/– versus WT). D–F: CD11b+F4/80+ macrophages harvested from the eyes (D), draining smLNs (E), and mLNs (F) of WT, Daf1–/–, and Daf1–/–C3ar1–/–C5ar1–/– mice were assayed for the same markers. Cells were also assayed for C5ar1 and C5L2. The fact that differences in ICOS-L levels between Daf1−/− and WT cells reach statistical significance reflects mouse numbers as other studies in the laboratory (M.G.S., J.L., F.A., and M.E.M., unpublished data) reproducibly have documented statistical significance. G and H: Human plasmacytoid DCs (pDCs; G) and CD4 T cells (H) were treated with siRNA targeting DAF or C3ar1 and C5ar1 for 72 hours, after which expression of CD40, B7.1, B7.2, CCR7, CCR9, PD-L1, and ICOS-L on pDCs (G) and expression of CD28, CD40 ligand, CCR7, CCR9, PD-1, and ICOS on CD4+ T cells (H) was assessed by flow cytometry. n = 10 per group (A–F); n = 3 (G and H). ∗∗P < 0.01. MFI, mean fluorescent intensity.

    Journal: The American Journal of Pathology

    Article Title: CD55 Is Essential for CD103 + Dendritic Cell Tolerogenic Responses that Protect against Autoimmunity

    doi: 10.1016/j.ajpath.2019.04.008

    Figure Lengend Snippet: Decay-accelerating factor (DAF) is required for the tolerogenic properties of CD103+ dendritic cells (DCs) and regulatory T cells. A–C: CD11c+ DCs harvested from the eyes (A), draining submandibular lymph nodes (smLNs; B), and mesenteric lymph nodes (mLNs; C) of wild-type (WT), Daf1–/–, and Daf1–/–C3ar1–/–C5ar1–/– mice were assayed for CD40, B7.1, B7.2, major histocompatibility complex (MHC) II, PD-L1, and ICOS-L by flow cytometry (Daf1–/– versus WT and Daf1–/–C3ar1–/–C5ar1–/– versus WT). D–F: CD11b+F4/80+ macrophages harvested from the eyes (D), draining smLNs (E), and mLNs (F) of WT, Daf1–/–, and Daf1–/–C3ar1–/–C5ar1–/– mice were assayed for the same markers. Cells were also assayed for C5ar1 and C5L2. The fact that differences in ICOS-L levels between Daf1−/− and WT cells reach statistical significance reflects mouse numbers as other studies in the laboratory (M.G.S., J.L., F.A., and M.E.M., unpublished data) reproducibly have documented statistical significance. G and H: Human plasmacytoid DCs (pDCs; G) and CD4 T cells (H) were treated with siRNA targeting DAF or C3ar1 and C5ar1 for 72 hours, after which expression of CD40, B7.1, B7.2, CCR7, CCR9, PD-L1, and ICOS-L on pDCs (G) and expression of CD28, CD40 ligand, CCR7, CCR9, PD-1, and ICOS on CD4+ T cells (H) was assessed by flow cytometry. n = 10 per group (A–F); n = 3 (G and H). ∗∗P < 0.01. MFI, mean fluorescent intensity.

    Article Snippet: Anti-murine C5ar2 (AKA C5L2; HP8015) was purchased from Hycult Biotech (Wayne, PA).

    Techniques: Flow Cytometry, Expressing